Relmada Therapeutics Inc (RLMD)


Stock Price Forecast

March 15, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Relmada Therapeutics Inc chart...

About the Company

relmada therapeutics (otcqb: rlmd) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of chronic pain. relmada has a diversified portfolio of four lead products at various stages of development including d-methadone (rel-1017) its n-methyl-d-aspartate (nmda) receptor antagonist for neuropathic pain; topical mepivacaine (rel-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (rel-1028) its oral dosage form of the opioid analgesic buprenorphine; and levocap er (rel-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. relmada’s product development efforts are guided by the internationally recognized scientific expertise of our research team. relmada’s approach is expected to reduce clinical development risks and

CEO

Sergio Traversa

Exchange

NASDAQ

Website

https://www.relmada.com/

$0M

Total Revenue

27

Employees

$163M

Market Capitalization

-1.25

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $RLMD News

Relmada Therapeutics FY 2023 Earnings Preview

on MSN ago, source:

Relmada Therapeutics is set to release their fiscal year earnings results on March 18th after the market closes.

Earnings Outlook For Relmada Therapeutics

16h ago, source:

Analysts estimate that Relmada Therapeutics will report an earnings per share (EPS) of $-0.83. Relmada Therapeutics bulls ...

RLMD Jan 2025 4.500 put

2d ago, source: Yahoo Finance

Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that it will report its financial results for the ...

RLMD Apr 2024 2.500 put

2d ago, source: Yahoo Finance

Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that it will report its financial results for the ...

Analysts’ Opinions Are Mixed on These Healthcare Stocks: ACADIA Pharmaceuticals (ACAD) and Enhabit, Inc (EHAB)

8d ago, source:

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on ACADIA Pharmaceuticals (ACAD – Research ...

Analysts Offer Insights on Healthcare Companies: Ocular Therapeutix (OCUL), Adaptimmune Therapeutics (ADAP) and Arcutis Biotherapeutics (ARQT)

5d ago, source:

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Ocular Therapeutix (OCUL – Research ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...